Related Experiment Video
Updated: Jul 11, 2026
07:39
Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper (cTfh) Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
Published on: January 7, 2019
t(6;14)(q15;q32) in a patient with CD5+CD10+ diffuse large B-cell lymphoma
Miyuki Hayama1, Nozomi Niitsu, Masaaki Higashihara
1Department of Hematology, Kitasato University, Sagamihara-shi, Kanagawa, Japan. mhayama@med.kitasato-u.ac.jp
International Journal of Hematology
|September 19, 2007
Summary
This study reports a rare case of CD5-positive, CD10-positive diffuse large B-cell lymphoma in a patient with hereditary spherocytosis. The lymphoma exhibited a unique chromosomal translocation, t(6;14)(q15;q32), highlighting the need for further research into lymphomagenesis mechanisms.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Co-occurrence of DLBCL with hereditary spherocytosis is uncommon.
- Specific immunophenotypic and cytogenetic profiles can influence DLBCL behavior and prognosis.
Observation:
- A 68-year-old male presented with systemic lymphadenopathy.
- Cervical lymph node biopsy revealed diffuse proliferation of large atypical lymphoid cells.
- Immunohistochemistry showed positivity for CD5, CD10, CD20, CD79a, and Bcl2, and negativity for CD3 and cyclin D1.
Findings:
- The patient was diagnosed with CD5+, CD10+ diffuse large B-cell lymphoma.
- Karyotypic analysis revealed complex chromosomal abnormalities, including add(5)(q13), del(6)(q13), add(17)(p11), add(19)(p11), add(19)(p13), and a non-random t(6;14)(q15;q32) translocation.
- Peripheral blood smear showed elliptocytosis, and a family history confirmed hereditary spherocytosis.
Implications:
- The presence of CD5 and CD10 markers in DLBCL, along with the specific t(6;14)(q15;q32) translocation, suggests a distinct subtype requiring further investigation.
- Understanding the lymphomagenesis mechanism in such cases is crucial for developing targeted therapies.
- The co-occurrence with hereditary spherocytosis warrants exploration of potential shared pathways or independent disease processes.
